UPPTHERA Inc.

Targeted protein degradation (TPD) is becoming a popular choice for Korean pharma firms looking for new drug modalities and growth engines. They are making diverse moves, largely seeking R&D collabora

South Korean bioventures felt a sharp deterioration in investor sentiment in the financing market in the second quarter, with venture capital financing declining and only one initial public offering l

For Yuhan Corporation , the past several years have marked a new beginning in terms of the development and globalization of novel drugs, and the pursuit of an open innovation approach to R&D has been

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Emmaus, Kainos Tie Up To Develop IRAK4